Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Exelixis files Investigational New Drug Application for XL418
February 27th, 2007
Exelixis, Inc. (EXEL) announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for XL418, a novel anticancer compound. XL418 is an inhibitor of protein kinase B (PKB or AKT) and S6 Kinase (S6K), key components of the phosphoinosotide-3 kinase (PI3K) signaling pathway. Activation of these kinases is a frequent event in human tumors, promoting cell growth, survival and resistance to chemotherapy and radiotherapy. "One of our drug development strategies is to systematically target key nodes in signaling pathways that are frequently deregulated in human tumors. An important component of this...
Source: Cancer Weekly (2007-02-27)
|
